IMUNON (IMNN) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

IMNN · Stock Price

USD 2.73-7.70 (-73.84%)

Market Cap: $10.8M

Historical price data

Overview

IMUNON is a clinical-stage biotech focused on developing novel DNA-based immunotherapies and vaccines using its proprietary non-viral delivery platforms. Its strategy centers on advancing IMNN-001, a TheraPlas™-IL-12 therapy, in a Phase 2 trial for advanced ovarian cancer while concurrently validating its PlaCCine DNA vaccine platform. The company aims to overcome the limitations of viral vectors by enabling safe, localized, and durable immune stimulation for oncology and infectious disease applications.

OncologyInfectious Diseases

Technology Platform

Proprietary non-viral DNA delivery platforms (TheraPlas™ for immunotherapies and PlaCCine for vaccines) designed to enable safe, localized, and durable in vivo production of therapeutic proteins or stimulation of immune responses.

Pipeline

16

16 drugs in pipeline3 in Phase 3

Drug	Indication	Stage
ThermoDox + Dummy infusion	Hepatocellular Carcinoma	Phase 3
ThermoDox + 5% Dextrose Solution	Hepatocellular Carcinoma	Phase 3
IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol ...	Epithelial Ovarian Cancer	Phase 3
Lyso-Thermosensitive Liposomal Doxorubicin + ThermoDox	Colon Cancer Liver Metastasis	Phase 2
cyclophosphamide + doxorubicin hydrochloride	Breast Cancer	Phase 2

Opportunities

A successful Phase 2 readout for IMNN-001 in ovarian cancer could unlock significant value, validate the core platform, and create opportunities in other peritoneal cancers.

The PlaCCine DNA vaccine platform represents a long-term, high-upside opportunity in the large and growing global vaccine market, particularly for rapid response to emerging pathogens.

Risk Factors

The company faces extreme binary risk from its lead Phase 2 trial.

Its micro-cap, pre-revenue status necessitates further dilutive financing, and it competes in crowded fields against much larger, well-resourced companies.

Competitive Landscape

IMUNON competes in ovarian cancer against developers of ADCs, cellular therapies, and other immunomodulators. In DNA vaccines, it faces competition from other non-viral delivery technologies and established viral vector platforms from both biotechs and large pharma. Its small size is a key competitive disadvantage.

More companies in Immunotherapy / Immuno-Oncology →More companies in United States →